Acera Surgical, Inc.

Acera Surgical is a bioscience company developing and commercializing engineered materials for regenerative medicine and soft tissue repair. The company pioneers electrospun fiber matrix technology—synthetic, fully resorbable scaffolds with sub-cellular fibers (sub-micron to micron diameter) that are structurally similar to native human extracellular matrix (ECM). These materials resist enzymatic degradation, support cellular infiltration and proliferation, and facilitate healing across the inflammatory and proliferation phases before complete resorption. Acera's flagship product, Restrata®, is the first electrospun fiber matrix indicated for wound management, including surgical and traumatic wounds, with Level I clinical evidence supporting its use in chronic diabetic foot ulcers and soft tissue repair applications. The product is available in multiple form factors: sheet, meshed (expandable up to 2x coverage), and micronized (MiniMatrix) for irregular topography. Cerafix® is a non-biologic, bioresorbable fibrous matrix indicated for dural repair and closure, designed to reduce postoperative cerebrospinal fluid leakage and support dural restoration. Acera's technology is backed by over ten years of academic and clinical research, multiple regenerative medicine patents, and clinical validation across surgical specialties including orthopedic trauma, general trauma, oncology, head and neck, plastic and reconstructive, and foot and ankle surgery. Products are composed of carefully selected polymers engineered for strength, flexibility, and effective healing without animal or human components.